Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 5/20 | 0.59 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.59 |
| ▸ | PTGFR | P43088 | 2/20 | 0.59 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PTGIR | P43119 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11596606 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11599710 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11596612 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11599718 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11596602 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11599713 | 1.00 | PTGER3 (0.59) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11515062 | 0.87 | PTGER3 (0.48) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11515066 | 0.87 | PTGER3 (0.48) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11737423 | 0.87 | PTGER2 (0.48) | PTGER3PTGER1TBXA2RPTGFRPTGER2 | |
| SCHEMBL11737415 | 0.87 | PTGER2 (0.48) | PTGER3PTGER1TBXA2RPTGFRPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333702-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | ORCHARD THERAPEUTICS EUROPE LTD (GB) | 2025-05-01 | — | — | US | disclosed |
| US-20250101381-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| CN-113631703-B | Using poloxacin viral conduction of amines | 瑞威帝基因传递股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-111212648-B | Compositions and methods for preventing or treating muscle disorders | 莱兰斯坦福初级大学评议会 | 2024-07-09 | — | — | CN | disclosed |
| CN-112481211-B | Cells with increased immunomodulation and methods of use and production thereof | 儿童医院公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4294919-A1 | MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11834668-B2 | Compounds for improved viral transduction | BLUEBIRD BIO, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230313227-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEREDITARY ANGIOEDEMA | ORCHARD THERAPEUTICS EUROPE LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230002784-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-107429232-B | Immunoregulatory enhanced cells and methods of use and production thereof | 菲特治疗公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220370509-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN'S DISEASE | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| EP-4058043-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN'S DISEASE | Orchard Therapeutics (Europe) Limited (GB) | 2022-09-21 | — | — | EP | disclosed |
| CN-115087455-A | Compositions and methods for treating or preventing Crohn's disease | 奥查德疗法(欧洲)有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2022178357-A1 | MAGNETIC DESCRIPTION MAGNETIC SHEAR BIOREACTOR APPARATUS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-25 | — | — | WO | disclosed |
| CN-114761567-A | Compositions and methods for modifying eukaryotic cells | 奥查德疗法(欧洲)有限公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-108220246-B | Compounds for improving viral transduction | 蓝鸟生物公司 | 2022-07-12 | — | — | CN | disclosed |
| CN-114561277-A | Methods and devices for conditioning cell populations for cell therapy | 得克萨斯州大学系统董事会 | 2022-05-31 | — | — | CN | disclosed |
| EP-3972599-A1 | COMBINATION FOR LOWERING SERUM PHOSPHATE IN A PATIENT | Ardelyx, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230313227-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEREDITARY ANGIOEDEMA | SERPINH1, SERPINB1, SERPINB6 | PTGER3 750/4885PTGER1 623/4885TBXA2R 306/4885 |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | CD4, CD74, HLA-DRB1 | PTGER3 1321/4885PTGER1 1381/4885TBXA2R 1062/4885 |
| US-20220370509-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CROHN'S DISEASE | NOD2, FABP2, TPMT | PTGER3 1753/4885PTGER1 1733/4885TBXA2R 3357/4885 |
| US-20230002784-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | PHAX, CD4, POLM | PTGER3 1197/4885PTGER1 685/4885TBXA2R 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.